Description

Alcon: The IOL Multi-Year Product Cadence—PanOptix Pro Today, Truel+ Next, and an Upgraded Vivity Targeting 2027 Mix Upside!

Alcon exited 2025 with a stronger second half and a particularly solid fourth quarter, but management continued to frame the environment as improved rather than fully normalized. Reported fourth quarter sales rose 7% to $2.7 billion, with Surgical up 6% and Vision Care up 7%. The performance reflected momentum in equipment, dry eye, and select premium lens categories, while also highlighting competitive pressure in implantables and more uneven conditions outside the U.S. The 2026 outlook for 5% to 7% top-line growth was positioned as a disciplined starting point that largely assumes market growth holds near recent levels, with incremental contribution from a broad set of launches, but with enough variability in both demand and product trajectories to justify a wide range.